Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5778-5784

  Trifan, Ovidiu C ^a   Durham, William F ^a   Salazar, Valerie S ^a   Horton, Jennifer ^a   Levine, Benjamin D ^a   Zweifel, Ben S ^a   Davis, Thomas W ^a   Masferrer, Jaime L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLON; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIARRHEA; DINOPROSTONE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HT29 CELLS; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; WEIGHT LOSS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037108880     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase 1. Proc. Natl. Acad. Sci. USA, 84: 5565-5569, 1987.
2. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
3. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
4. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol., 11: 909-913, 1993.
5. Pitot, H. C., and Goldberg, R. M. Future directions in adjuvant therapy for stage III colon carcinoma. Oncology (Huntingt.), 15: 31-36, 2001.
6. Saltz, L. Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. Oncology (Huntingt.), 14: 47-50, 2000.
7. Rothenberg, M. L., and Blanke, C. D. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin. Oncol., 26: 632-639, 1999.
8. Kambe, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., and Yoshino, M. A late Phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers. Proc. Am. Soc. Clin. Oncol., 12: 198, 1993.
9. Futatsuki, K., Wakui, A., Nakao, I., Sakata, Y., Kambe, M., Shimada, Y., Yoshino, M., Taguchi, T., and Ogawa, N. Late Phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn. J. Cancer Chemother., 21: 1033-1038, 1994.
10. Rocha Lima, C., Savarese, D., Bruckner, H., Dudek, A., Eckardt, J., Hainsworth, J., Lester, E., Compton, L., Locker, P., and Elfring, G. Multicenter Phase II trial of first-line irinotecan and gemcitabine (irimogem) in patients with locally advanced or metastatic pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol., 9: 263a, 2000.
11. Rocha Lima, C. M., Eckardt, J. R., Leong, S. S., Sherman, C. A., Perkel, J. A., Putman, T., Safa, A. R., Bahadori, H. R., and Green, M. R. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin. Oncol., 26: 43-50, 71-72, 1999.
12. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., and Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (Bethesda), 83: 1164-1168, 1991.
13. Hecht, J. R. Gastrointestinal toxicity of irinotecan. Oncology (Huntingt.), 12: 72-78, 1998.
14. Kurita, A., Kado, S., Kaneda, N., Onoue, M., Hashimoto, S., and Yokokura, T. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Cancer Chemother. Pharmacol., 46: 211-220, 2000.
15. Bleiberg, H., and Cvitkovic, E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective. Eur. J. Cancer, 32A: S18-S23, 1996.
16. Kawato, Y., Sekiguchi, M., Akahane, K., Tsutomi, Y., Hirota, Y., Kuga, H., Suzuki, W., Hakusui, H., and Sato, K. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J. Pharm. Pharmacol., 45: 444-448, 1993.
17. Gandia, D., Abigerges, D., Armand, J. P., Chabot, G., Da Costa, L., De Forni, M., Mathieu-Boue, A., and Herait, P. CPT-11-induced cholinergic effects in cancer patients. J. Clin. Oncol., 11: 196-197, 1993.
18. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 343: 905-914, 2000.
19. 2 and water absorbtion of large intestine in rats. Jpn. J. Pharmacol., 75: 399-405, 1997.
20. - secretion in isolated rat colon. J. Physiol., 505: 133-144, 1997.
21. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer N. Engl. J. Med., 325: 1593-1596, 1991.
22. Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D., and Heath, C. W., Jr. Aspirin use and risk of fatal cancer. Cancer Res., 53: 1322-1327, 1993.
23. Schreinemachers, D. M., and Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 5: 138-146, 1994.
24. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.
25. Harris, R. E., Namboodiri, K. K., and Farrar, W. B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 7: 203-205, 1996.
26. Howe, L. R., Subbaramaiah, K., Brown, A. M., and Dannenberg, A. J. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer, 8: 97-114, 2001.
27. Dempke, W., Rie, C., Grothey, A., and Schmoll, H. J. Cyclooxygenase-2: A novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 127: 411-417, 2001.
28. Kirschenbaum, A., Liu, X., Yao, S., and Levine, A. C. The role of cyclooxygenase-2 in prostate cancer. Urology. 58: 127-131, 2001.
29. Prescott, S. M., and Fitzpatrick, F. A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta. 1470: M69-M78, 2000.
30. Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., and DuBois, R. N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest., 105: 1589-1594, 2000.
31. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woemer, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., and Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60: 1306-1311, 2000.
32. Leahy, K. M., Koki, A. T., and Masferrer, J. L. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem., 7: 1163-1170, 2000.
33. Hansen-Petrik, M. B., McEntee, M. F., Johnson, B. T., Obukowicz, M. G., Masferrer, J., Zweifel, B., Chiu, C. H., and Whelan, J. Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis. Cancer Lett., 175: 157-163, 2002.
34. Tomozawa, S., Nagawa, H., Tsuno, N., Hatano, K., Osada, T., Kitayama, J., Sunami, E., Nita, M. E., Ishihara, S., Yano, H., Tsuruo, T., Shibata, Y., and Muto, T. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer. 81: 1274-1279, 1999.
35. His, L. C., Baek, S. J., and Eling, T. E. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp. Cell Res., 256: 563-570, 2000.
36. Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., and Isakson, P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA, 95: 13313-13318, 1998.
37. Paulson, S. K., Kaprak, T. A., Gresk, C. J., Fast, D. M., Baratta, M. T., Burton, E. G., Breau, A. P., and Karim, A. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm. Drug. Dispos., 20: 293-299, 1999.
38. 2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med., 184: 883-891, 1996.
39. Taketo Makoto, M. Cyclooxygenase-2 Inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. (Bethesda), 90: 1529-1536, 1998.
40. Taketo Makoto, M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst. (Bethesda), 90: 1609-1620, 1998.
41. Ziegler, J. Cancer and arthritis share underlying processes. J. Natl. Cancer Inst. (Bethesda). 90: 802-803, 1998.
42. Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., Haudenschild, C., Lane, T. F., and Hla, T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem., 276: 18563-18569, 2001.
43. Leahy, K. M., Omberg, R. L., Wang, Y., Zweifel, B. S., Koki, A. T., and Masferrer, J. L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res., 62: 625-631, 2002.
44. Karim, A., Boynton, J., Wallemark, C., Kent, J., and Frazier-O'Bannon, L. Effects of celecoxib (cyp2c9 substrate) and omeprazole (cyp2c9 substrate/inhibitor) on systemic exposure to each other. AAPS. Pharm. Sci., 3: T3669, 2001.
45. 2 stimulates rat and human colonic mucin exocytosis via the EP(4) receptor. Gastroenterology, 117: 1352-1362, 1999.
46. - secretion by antidiarrhea drug loperamide in isolated rat colon. J. Pharmacol. Exp. Ther., 295: 233-238, 2000.
47. Lenfers, B. H., Loeffler, T. M., Droege, C. M., and Hausamen, T. U. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann. Oncol., 10: 1251-1253, 1999.
48. Fujita, J., Mestre, J. R., Zeldis, J. B., Subbaramaiah, K., and Dannenberg, A. J. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res., 7: 3349-3355, 2001.
49. Onn, A., Tseng, J. E., and Herbst, R. S. Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy. Clin. Cancer Res., 7: 3311-3313, 2001.
50. Govindarajan, R., Heaton, K. M., Broadwater, R., Zeitlin, A., Lang, N. P., and Hauer-Jensen, M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet, 356: 566-567, 2000.
51. Savarese, D., Al-Zoubi, A., and Boucher, J. Glutamine for irinotecan diarrhea. J. Clin. Oncol., 18: 450-451, 2000.
52. 2 synthesis and breast cancer growth. J. Surg. Res., 63: 293-297, 1996.
53. Glinghammar, B., and Rafter, J. Colonic luminal contents induce cyclooxygenase 2 transcription in human colon carcinoma cells. Gastroenterology, 120: 401-410, 2001.
54. Arbabi, S., Rosengart, M. R., Garcia, I., Jelacic, S., and Maier, R. V. Epithelial cyclooxygenase-2 expression: A model for pathogenesis of colon cancer. J. Surg. Res., 97: 60-64, 2001.
55. Kojima, M., Morisaki, T., Izuhara, K., Uchiyama, A., Matsunari, Y., Katano, M., and Tanaka, M. Lipopolysaccharide increases cyclooxygenase-2 expression in a colon carcinoma cell line through nuclear factor-κB activation. Oncogene. 19: 1225-1231, 2000.